Lumira Ventures

Puzzle Medical Devices develops innovative heart pump solutions to treat advanced heart failure. Its flagship product, ModulHeart, is a modular percutaneous device designed to reduce cardiac afterload and improve renal perfusion. The device's unique design enables safe percutaneous implantation, supporting both renal and cardiac function with low risk of complications. Puzzle Medical has successfully completed its first-in-human study, demonstrating improvements in cardiac and kidney function.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Sound Blade Medical is an early-stage medical device company that specializes in developing innovative, non-invasive therapies using endoscopic histotripsy. This technology employs focused ultrasound, guided by real-time imaging, to precisely destroy targeted tissue without heat, ionizing radiation, or surgical invasion. The company aims to revolutionize healthcare by enhancing endoscopic procedures, offering a more precise and safer alternative to traditional treatments.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

Founded in 2014, Cyrano Therapeutics develops intranasal therapies for chronic taste and smell disorders. Its lead product, CYR-001, repurposes an approved molecule to restore function with minimal side effects, as demonstrated in a pilot study. The company aims to improve patients' quality of life by addressing these often overlooked conditions.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

PIC Therapeutics, Inc. is a biotechnology company dedicated to advancing cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and headquartered in Boston, Massachusetts, the company develops precision-based therapeutics that target the master switch of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This innovative approach has the potential to simultaneously address multiple oncogenic drivers, paving the way for a new generation of cancer therapies that could significantly enhance patient outcomes.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Congruence Therapeutics is a biotechnology company that integrates computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, using structural bioinformatics, computational chemistry, and machine learning to identify and optimize pharmacological stabilizers at accelerated pace and scale to correct disease pathogenesis.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through targeted protein degradation. It specializes in developing innovative small molecule degraders, initially targeting cancer, using its proprietary PRODEGY platform built upon expertise in Cereblon binding.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Notch Therapeutics is a Toronto-based company developing immune cell therapies using induced pluripotent stem cell technology to create gene-edited allogeneic T cells. Its platform enables precise control of Notch signaling during T-cell development, enabling scalable manufacture of a uniform supply of therapeutic T cells for cancer indications such as non-Hodgkin lymphoma, leukemia, and multiple myeloma. The approach aims to overcome bottlenecks in cell therapy development by integrating advanced product design with commercially compatible processes, supporting a next-generation pipeline of cell therapies.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Founded in 2014, Cyrano Therapeutics develops intranasal therapies for chronic taste and smell disorders. Its lead product, CYR-001, repurposes an approved molecule to restore function with minimal side effects, as demonstrated in a pilot study. The company aims to improve patients' quality of life by addressing these often overlooked conditions.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.

IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.

Bright Angel Therapeutics develops novel therapeutics targeting stress responses crucial for fungi's survival, virulence, and drug resistance. Its platform aims to enhance current treatment efficacy and eliminate drug resistance, combating life-threatening fungal infections.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Founded in 2013, Bardy Diagnostics specializes in developing advanced cardiac monitoring devices. Its flagship product is the Carnation Ambulatory Monitor (CAM), a discreet and comfortable patch monitor designed to capture clear P-wave signals for accurate arrhythmia detection. The company also offers BDxCONNECT, a patient management system that aids clinical decision-making by providing easy access to CAM reports.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Founded in 2003, Exact Imaging specializes in developing high-resolution micro-ultrasound systems for real-time imaging and guided biopsies, primarily focused on the urological market for prostate cancer detection. Its flagship product, ExactVu™, operates at 29 MHz, offering unmatched resolution for visualizing and targeting suspicious regions, while also facilitating systematic TRUS biopsies.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Medexus Pharmaceuticals is a specialty pharmaceutical company focused on the North American market. It develops, markets, and distributes a portfolio of therapies addressing rare diseases, autoimmune conditions, pediatric needs, oncology, and allergy. The company’s products include Rasuvo and Metoject (methotrexate) for rheumatoid arthritis and other autoimmune diseases; IXINITY for Hemophilia B; Rupall for seasonal and perennial allergic rhinitis and chronic spontaneous urticaria; Cuvposa for sialorrhea in children with neurologic conditions; Gliolan for intraoperative visualization of brain tumors; and Treosulfan as a conditioning agent before stem cell transplantation. Its operations span Canada and the United States, supported by a North American commercial platform that sells to wholesalers, distributors, healthcare facilities, and specialty pharmacies. Originally known as Pediapharm, the company rebranded as Medexus in 2018 and is based in Verdun, Canada.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

KalGene Pharmaceuticals Inc. is a private biotechnology company based in Candiac, Canada, focused on developing precision medicine for the treatment of Alzheimer’s disease. Established in 2006, KalGene collaborates with leading clinician-scientists and academic institutions across North America and Europe. The company specializes in creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates. Through personalized medicine, KalGene seeks to predict patient responses to specific therapies before treatment begins, enabling physicians to tailor interventions based on individual biological signatures and needs.

Founded in 2003, Exact Imaging specializes in developing high-resolution micro-ultrasound systems for real-time imaging and guided biopsies, primarily focused on the urological market for prostate cancer detection. Its flagship product, ExactVu™, operates at 29 MHz, offering unmatched resolution for visualizing and targeting suspicious regions, while also facilitating systematic TRUS biopsies.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Founded in 2003, Exact Imaging specializes in developing high-resolution micro-ultrasound systems for real-time imaging and guided biopsies, primarily focused on the urological market for prostate cancer detection. Its flagship product, ExactVu™, operates at 29 MHz, offering unmatched resolution for visualizing and targeting suspicious regions, while also facilitating systematic TRUS biopsies.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

KalGene Pharmaceuticals Inc. is a private biotechnology company based in Candiac, Canada, focused on developing precision medicine for the treatment of Alzheimer’s disease. Established in 2006, KalGene collaborates with leading clinician-scientists and academic institutions across North America and Europe. The company specializes in creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates. Through personalized medicine, KalGene seeks to predict patient responses to specific therapies before treatment begins, enabling physicians to tailor interventions based on individual biological signatures and needs.

Engage Therapeutics, Inc. is a biopharmaceutical company based in Summit, New Jersey, focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. Its lead investigational product, Staccato alprazolam, is a small, handheld drug-device combination designed for the rapid cessation of active and acute seizures. Utilizing an FDA-approved delivery system, the Staccato device administers alprazolam, an established benzodiazepine, in a single inhalation. The product has shown promise in a Phase 2a proof of concept study, which indicated potential reductions in seizures within a photosensitivity model. Engage Therapeutics is advancing Staccato alprazolam through clinical development, employing a 505(b)(2) regulatory pathway to facilitate its market entry.

Stellar Biotechnologies, Inc. is a biotechnology company that specializes in the sustainable manufacture of keyhole limpet hemocyanin (KLH), an immune-stimulating protein. KLH is utilized as a carrier molecule in therapeutic vaccine development targeting various conditions, including cancers, immune disorders, Alzheimer's disease, and inflammatory diseases. The company offers KLH in multiple grades and formulations for drug development and research applications, as well as in vitro diagnostic kits for research and preclinical use. Stellar's clientele includes biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Based in Port Hueneme, California, Stellar Biotechnologies is recognized for its contributions to advancing immunotherapies and assessing immune system function through its innovative products.

Edesa Biotech is a clinical-stage company focused on developing treatments for dermatological and anorectal diseases. Its primary focus is on creating novel, safe, and potent alternatives to steroids, particularly for conditions like allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa's lead asset, EB01, is a non-steroidal anti-inflammatory molecule that has shown promising results in clinical studies.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Founded in 2003, Exact Imaging specializes in developing high-resolution micro-ultrasound systems for real-time imaging and guided biopsies, primarily focused on the urological market for prostate cancer detection. Its flagship product, ExactVu™, operates at 29 MHz, offering unmatched resolution for visualizing and targeting suspicious regions, while also facilitating systematic TRUS biopsies.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

Opsens Inc. is a Canadian company that specializes in developing, manufacturing, and selling fiber optic sensors for various applications, primarily in interventional cardiology and industrial markets. It operates in two main segments: Medical and Industrial. The Medical segment focuses on physiological measurements, including Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR), and offers products such as the OptoWire, an advanced optical pressure guidewire, and miniature optical sensors for pressure and temperature measurement. These sensors are designed for integration into medical devices, catering to needs in areas like transcatheter aortic valve replacement. The Industrial segment provides fiber optic sensing solutions for diverse applications, including life sciences, energy, and civil engineering. Opsens markets its products through a direct sales force and distributors across the United States, Japan, Canada, and internationally, with its headquarters located in Québec, Canada.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Zymeworks is a biotechnology company focused on optimizing protein-based therapeutics, particularly for cancer treatment. It uses proprietary computational methods to engineer differentiated product candidates, with its lead asset zanidatamab in multiple clinical trials targeting HER2-expressing solid tumors.

This national mobile wellness rewards initiative harnesses the public’s affinity for popular loyalty points, the convenience of smart phone technology and Canadians’ natural desire to lead healthier lives. It is this unique combination that results in such a powerful “nudge” platform – in support of a healthier

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

First Aid Shot Therapy, founded in 2010 and headquartered in Burlingame, California, specializes in clinical beverages aimed at addressing acute and chronic health needs. The company offers a variety of easy-to-swallow, single-dose products that provide rapid relief for common everyday symptoms such as hangover, pain, sleep issues, cold, allergy, and heartburn. By focusing on fast-acting solutions, First Aid Shot Therapy aims to help consumers manage their symptoms quickly and conveniently.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, particularly targeting diabetic nephropathy. Founded in 2005 and headquartered in Research Triangle Park, North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to address complications associated with diabetes. This drug binds to a specific molecular target within the αVβ3 receptor, aiming to mitigate the harmful effects of hyperglycemia and improve patient outcomes. Vascular Pharmaceuticals operates at the intersection of biotechnology and healthcare, committed to innovative solutions for diabetes-related complications.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

OsteoQC Inc is a company that develops new drugs and therapies for the treatment of bone-related diseases.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, founded in 2003. The company specializes in the design and development of non-fusion motion preservation systems for treating degenerative diseases of the cervical and lumbar spine. Its flagship products, the M6-C and M6-L artificial discs, offer innovative options for artificial cervical and lumbar disc replacements, respectively. These discs are uniquely engineered to replicate the anatomical and biomechanical properties of natural intervertebral discs by incorporating an artificial nucleus and annulus. Spinal Kinetics collaborates with spine surgeons to enhance the effectiveness of its devices, which are distributed in various countries, including Australia, Germany, Spain, and the United Kingdom. The company operates as a subsidiary of Orthofix Medical Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Aurinia Pharmaceuticals is a biopharmaceutical company dedicated to developing and delivering therapies for patients with serious autoimmune diseases, particularly those with high unmet medical needs. Its lead product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for treating active lupus nephritis.

Aptose Biosciences is a clinical-stage biotechnology company focused on discovering and developing personalized cancer therapies. Its pipeline includes small molecule drugs designed for single-agent efficacy and to enhance the effectiveness of other anti-cancer treatments, without overlapping toxicities.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Argos Therapeutics is a biotechnology company specializing in developing immunotherapy treatments for cancer and infectious diseases. It focuses on personalized immunotherapies using its proprietary Arcelis technology platform, with product candidates including rocapuldencel-T for metastatic renal cell carcinoma and AGS-004 for HIV.

Aurinia Pharmaceuticals is a biopharmaceutical company dedicated to developing and delivering therapies for patients with serious autoimmune diseases, particularly those with high unmet medical needs. Its lead product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for treating active lupus nephritis.

Vendorlink.ca is a provider of web-based vendor management solutions specifically designed for the healthcare sector. The company offers a platform that enables hospitals to enforce their policies while ensuring patient safety and privacy through effective vendor training and monitoring. Its comprehensive tools facilitate the management of vendor credentials, activities, and behaviors, allowing healthcare facilities to maintain high standards. Additionally, Vendorlink.ca employs a dedicated team to verify each vendor's credentials before they are published on the vendor's profile, ensuring accuracy and reliability. For vendors, the platform functions as a third-party credentialing system, granting hospitals instant access to essential credentials at all times.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.